Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

[1]  J. Timsit,et al.  Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients , 2020, The Journal of antimicrobial chemotherapy.

[2]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.

[3]  M. Raux,et al.  Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis , 2020, Critical Care.

[4]  M. Battegay,et al.  Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations , 2020, Antimicrobial Agents and Chemotherapy.

[5]  S. Shakir,et al.  Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment , 2020, Drug Safety.

[6]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[7]  P. Horby,et al.  Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review , 2020, BMJ.

[8]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[9]  Eun Ji Kim,et al.  Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets , 2020, mBio.

[10]  F. Raffi,et al.  Lopinavir pharmacokinetics in COVID-19 patients , 2020, The Journal of antimicrobial chemotherapy.

[11]  Lee M. Tatham,et al.  Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics , 2020, Clinical pharmacology and therapeutics.

[12]  Guo‐Jun Zhang,et al.  Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection , 2020, European Respiratory Journal.

[13]  E. Clementi,et al.  Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? , 2020, The Journal of antimicrobial chemotherapy.

[14]  A. Zoufaly,et al.  Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) , 2020, Annals of Internal Medicine.

[15]  E. Clementi,et al.  Does lopinavir really inhibit SARS-CoV-2? , 2020, Pharmacological Research.

[16]  E. Castañón,et al.  A Trial of Lopinavir-Ritonavir in Covid-19. , 2020, The New England journal of medicine.

[17]  Xuhui Huang,et al.  Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.

[18]  C. Whittaker,et al.  Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.

[19]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[20]  L. Hong,et al.  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. , 2020, European review for medical and pharmacological sciences.

[21]  Xiu-Jie Wang,et al.  Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines , 2020, Journal of Genetics and Genomics.

[22]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[23]  Jian-Piao Cai,et al.  Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.

[24]  T. Bestebroer,et al.  Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.

[25]  J. N. van den Anker,et al.  Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in Children , 2011, Journal of acquired immune deficiency syndromes.

[26]  V. Lee,et al.  Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors , 2008, Journal of Theoretical Biology.

[27]  Y. Guan,et al.  In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds , 2004, Journal of Clinical Virology.

[28]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.